A genetic mutation of the H1N1 influenza virus resistant to the Rapiacta anti-influenza drug has been detected in a 5-year-old patient, according to the National Institute of Infectious Diseases.
It is likely the first case in Japan concerning a patient treated with the intravenous drip medicine introduced in January 2010.
According to a report recently posted by the institute on its website, a genetic mutation was found in a virus from the child who was treated with Rapiacta after testing positive for the type A influenza virus last month.
It is likely the first case in Japan concerning a patient treated with the intravenous drip medicine introduced in January 2010.
According to a report recently posted by the institute on its website, a genetic mutation was found in a virus from the child who was treated with Rapiacta after testing positive for the type A influenza virus last month.
Comment